DLK inhibitor (Belfer Neurodegeneration Consortium)

This dual leucine zipper kinase (DLK) inhibitor is a small-molecule therapeutic candidate developed by the Belfer Neurodegeneration Consortium at MD Anderson Cancer Center. DLK is a key regulator of the neuronal stress response; its activation leads to axonal degeneration and neuronal apoptosis in various neurodegenerative conditions. By inhibiting DLK, this compound aims to preserve neuronal integrity and prevent the cognitive and sensory deficits associated with neurodegeneration. The program is currently in preclinical development, targeting a range of conditions including Alzheimer's disease, chemotherapy-induced peripheral neuropathy (CIPN), and chemotherapy-related cognitive impairment, commonly referred to as chemobrain.

Other names

dual leucine zipper kinase inhibitorDLK inhibitor